[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532969":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":53,"collaborators":55,"id":65,"slug":7,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":7,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":7,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":7,"briefSummary":78,"conditions":79,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Texas A&M University","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Kenneth S Ramos, MD","Texas A&M IBT","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","7136777740","kramos@tamu.edu",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"The Interprofessional Pharmacogenomics (IPGx) Clinic","RECRUITING","Bryan","Texas","77802","United States",{"type":27,"coordinates":28},"Point",[29,30],-96.36996,30.67436,{"lat":30,"lon":29},[33,37,41,43,45,47,49,51],{"name":34,"role":15,"phone":35,"phoneExt":7,"email":36},"Gabriel Neal, MD","979-436-0399","gneal@tamu.edu",{"name":38,"role":15,"phone":39,"phoneExt":7,"email":40},"DeLona Bacote, MS","713-677-7735","dabacote@tamu.edu",{"name":42,"role":12,"phone":7,"phoneExt":7,"email":7},"Kenneth S Ramos, MD,PhD",{"name":34,"role":44,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":46,"role":44,"phone":7,"phoneExt":7,"email":7},"Sara Rogers, PharmD",{"name":48,"role":44,"phone":7,"phoneExt":7,"email":7},"George Udeani, PharmD",{"name":50,"role":44,"phone":7,"phoneExt":7,"email":7},"Asim Abu-Baker, PharmD",{"name":52,"role":44,"phone":7,"phoneExt":7,"email":7},"Rick Silva, PhD, MBA",{"type":54,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[56,59,61,63],{"name":57,"class":58},"InnovativeGx","UNKNOWN",{"name":60,"class":58},"Texas A&M Health Family Care Clinic",{"name":62,"class":58},"iC42 Clinical Research and Development",{"name":64,"class":58},"Goldblatt systems","100532969",false,"NCT06219720","The Texas Interprofessional Pharmacogenomics (IPGx)","The Texas Interprofessional Pharmacogenomics (IPGx) PILOT Cohort","Inclusion Criteria:\n\n* People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs\n* Ability to give and comprehend the consent process.\n* Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.\n* All genders.\n* Age 45 and over\n\nExclusion Criteria:\n\n* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.\n* Admitted to hospice.\n* Patient has ever been diagnosed with Hepatitis B or C.\n* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \\>10, ALT or AST \\>100U\u002FL or an AST\u002FALT ratio \\>2\n* Patients taking imidazole antifungal medication.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease\n* Pregnant patients will be excluded\n* Unable\u002Funwilling to consent.\n* Unable to verbally communicate and comprehend English\u002FSpanish language.","ALL","45 Years",{"count":74,"type":75},50,"ESTIMATED","180 Days","OBSERVATIONAL","The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity\u002Fsaturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.",[80],"Adverse Drug Reaction","2025-09-05",{"date":83,"type":84},"2025-09-12","ACTUAL",{"date":86,"type":84},"2021-12-15",{"date":88,"type":75},"2027-11",{"name":5,"class":6},1]